WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.95 --0%
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 14 | New: 59
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 14 | New: 59
Join SI Premium – FREE
WestPark Capital initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $4.50.
For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.
Shares of Akebia Therapeutics closed at $0.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- Wedbush Assumes Tenable (TENB) at Underperform
- ARC Group to acquire Malaysia's Firstborn Top Capital in $1.09B deal
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
